Shilpa Medicare Limited Asset Resilience Ratio
Shilpa Medicare Limited asset resilience ratio. Shilpa Medicare Limited (SHILPAMED) has an Asset Resilience Ratio of 1.65% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See SHILPAMED defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Shilpa Medicare Limited (2006–2025)
Asset resilience ratio of Shilpa Medicare Limited from 2006 to 2025. This chart shows how Shilpa Medicare Limited's Asset Resilience Ratio has changed over time. Read Shilpa Medicare Limited (SHILPAMED) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Shilpa Medicare Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Shilpa Medicare Limited balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs219.67 Million | 0.63% |
| Short-term Investments | Rs355.98 Million | 1.02% |
| Total Liquid Assets | Rs575.65 Million | 1.65% |
Asset Resilience Insights
- Limited Liquidity: Shilpa Medicare Limited maintains only 1.65% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shilpa Medicare Limited Industry Peers by Asset Resilience Ratio
Compare Shilpa Medicare Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Shilpa Medicare Limited Asset Resilience Ratio by Year (2006–2025)
Shilpa Medicare Limited asset resilience ratio by year from 2006 to 2025. The table below shows the annual Asset Resilience Ratio data for Shilpa Medicare Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 1.00% | Rs332.58 Million ≈ $3.60 Million |
Rs33.11 Billion ≈ $358.04 Million |
+0.76pp |
| 2024-03-31 | 0.25% | Rs76.57 Million ≈ $828.03K |
Rs30.93 Billion ≈ $334.52 Million |
-0.52pp |
| 2023-03-31 | 0.76% | Rs221.92 Million ≈ $2.40 Million |
Rs29.04 Billion ≈ $314.05 Million |
+0.56pp |
| 2022-03-31 | 0.21% | Rs59.10 Million ≈ $639.17K |
Rs28.75 Billion ≈ $310.97 Million |
-5.55pp |
| 2021-03-31 | 5.75% | Rs1.52 Billion ≈ $16.41 Million |
Rs26.38 Billion ≈ $285.24 Million |
+5.64pp |
| 2020-03-31 | 0.12% | Rs23.25 Million ≈ $251.39K |
Rs19.89 Billion ≈ $215.12 Million |
+0.12pp |
| 2019-03-31 | 0.00% | Rs216.00K ≈ $2.34K |
Rs16.10 Billion ≈ $174.12 Million |
-10.45pp |
| 2018-03-31 | 10.45% | Rs1.57 Billion ≈ $16.94 Million |
Rs14.99 Billion ≈ $162.13 Million |
-12.06pp |
| 2017-03-31 | 22.50% | Rs3.10 Billion ≈ $33.48 Million |
Rs13.76 Billion ≈ $148.79 Million |
+16.69pp |
| 2016-03-31 | 5.81% | Rs596.32 Million ≈ $6.45 Million |
Rs10.26 Billion ≈ $110.94 Million |
-1.55pp |
| 2015-03-31 | 7.36% | Rs666.18 Million ≈ $7.20 Million |
Rs9.05 Billion ≈ $97.82 Million |
+5.82pp |
| 2014-03-31 | 1.54% | Rs104.53 Million ≈ $1.13 Million |
Rs6.78 Billion ≈ $73.30 Million |
-10.04pp |
| 2013-03-31 | 11.58% | Rs638.42 Million ≈ $6.90 Million |
Rs5.51 Billion ≈ $59.63 Million |
-4.13pp |
| 2012-03-31 | 15.71% | Rs680.22 Million ≈ $7.36 Million |
Rs4.33 Billion ≈ $46.84 Million |
+8.99pp |
| 2011-03-31 | 6.72% | Rs232.84 Million ≈ $2.52 Million |
Rs3.47 Billion ≈ $37.48 Million |
+4.19pp |
| 2010-03-31 | 2.53% | Rs65.89 Million ≈ $712.58K |
Rs2.61 Billion ≈ $28.20 Million |
-2.47pp |
| 2009-03-31 | 4.99% | Rs110.23 Million ≈ $1.19 Million |
Rs2.21 Billion ≈ $23.88 Million |
+0.03pp |
| 2008-03-31 | 4.96% | Rs89.60 Million ≈ $969.04K |
Rs1.80 Billion ≈ $19.52 Million |
-7.61pp |
| 2007-03-31 | 12.58% | Rs80.79 Million ≈ $873.69K |
Rs642.29 Million ≈ $6.95 Million |
-5.53pp |
| 2006-03-31 | 18.11% | Rs82.15 Million ≈ $888.47K |
Rs453.74 Million ≈ $4.91 Million |
-- |
About Shilpa Medicare Limited
Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, … Read more